Artivion Inc. Common Stock (AORT)

FairStock Score: 39/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Artivion as a specialized medical-device maker with real products and recurring procedural demand, not a commodity. Sales have grown: in fiscal year 2025, the year ended 2025-12-31, revenue was $441.3 million, up from $388.5 million in fiscal year 2024, the year ended 2024-12-31, and $354.0 million in fiscal year 2023, the year ended 2023-12-31. It also narrowed losses: net income was $9.8 million, or diluted EPS $0.21, in fiscal year 2025, after net losses of $13.4 million, or diluted EPS -$0.32, in fiscal year 2024 and $30.7 million, or diluted EPS -$0.75, in fiscal year 2023. That matches the FairStock Lynch category of TURNAROUND: returned to profit after a loss within the last three years. But the latest filed quarter, fiscal Q2 2026 ended 2026-06-30, showed revenue of $125.8 million and a net loss of $13.5 million, or diluted EPS -$0.28. So improvement is not linear. Financial health worries me: FairStock data show D/E 0.92, TTM free cash flow -$9.2 million, FCF yield -0.9%, Altman Z-score 1.30, and Piotroski F-score 1/9. FairStock calculations also show ROCE of only 2.56% and ROE -0.73%, so capital returns are poor. At the 2026-10-13 close of $21.36, FairStock calculations show P/B 2.33, EV/EBITDA 26.87, and a negative P/E. FairStock Score 39/100 and the stock near the low end of its 52-week range $19.16-$48.25 suggest expectations have reset, but Graham would demand a margin of safety from earnings and assets, not just a turnaround hope. The business may have a moat in specialized aortic and cardiac devices, but current numbers show a fragile, uneven turnaround. I would want consistent positive free cash flow and lower leverage before calling it a value investment.

In plain English: Artivion makes heart valves, stent grafts and implantable human tissues used in heart and blood-vessel procedures. Sales are growing, but the company lost money in its latest reported quarter and has weak cash generation and meaningful debt. At $21.36, the price looks more like a bet on a turnaround than a clear bargain based on current profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer